FOR UK HEALTHCARE PROFESSIONALS ONLY
Adverse events should be reported. Reporting forms and information can be found at:

Adverse events should also be reported to Aspire Pharma Ltd on 01730 231148.www.mhra.gov.uk/yellowcard

For more information about Biquelle XL, please click here for the prescribing information.

Information

Legal Class: POM

Active Substances: Quetiapine fumarate

Summary of Product Characteristics and Patient Information Leaflet

The link below will take you to the electronic Medicines Compendium (eMC) website.

By using the link below you will leave the Biquelle website and be re-directed to an external site; Aspire Pharma is not responsible for the content on external websites.

Biquelle XL 50mg prolonged-release tablets:

View SmPC              View PIL

Biquelle XL 150mg prolonged-release tablets:

View SmPC              View PIL

Biquelle XL 200mg prolonged-release tablets:

View SmPC              View PIL

Biquelle XL 300mg prolonged-release tablets:

View SmPC              View PIL

Biquelle XL 400mg prolonged-release tablets: 

View SmPC              View PIL

Biquelle XL 600mg prolonged-release tablets: 

View SmPC              View PIL

More products available
in this range:
Click to view their
individual websites

BIQ1010269N1_APR2023